Nanoform Finland Plc – Manager’s transactions – June 10, 2020 at 02:00 p.m. Finnish time
Manager’s transaction related to Nanoform Finland Plc’s CFO and member of the Board of Directors Albert Hæggström’s subscription of shares in relation to the initial public offering on June 4, 2020 for which trades settled on June 8, 2020.
Nanoform Finland Plc – Managers’ Transactions
____________________________________________
Person subject to the notification requirement
Name: Haeggström Albert
Position: Member of the Board/Deputy member
Issuer: Nanoform Finland Plc
LEI: 743700JJO2NU8LBS1592
Notification type: INITIAL NOTIFICATION
Reference number: 743700JJO2NU8LBS1592_20200610102756_7
____________________________________________
Transaction date: 2020-06-08
Venue: FIRST NORTH FINLAND (FNFI)
Instrument type: SHARE
ISIN: FI4000330972
Nature of the transaction: SUBSCRIPTION
Transaction details
(1): Volume: 30,300 Unit price: 3.45 EUR
Aggregated transactions
(1): Volume: 30,300 Volume weighted average price: 3.45 EUR
Further enquiries:
Albert Hæggström, CFO
albert.haeggstrom@nanoform.com
+358 29 370 0150
Henri von Haartman, Director of Investor Relations
hvh@nanoform.com
+46 7686 650 11
Certified Adviser: Danske Bank A/S, Finland Branch, +358 40 562 1806
Nanoform in brief
Nanoform is an innovative nanoparticle medicine enabling company. Nanoform works together with pharma and biotech partners globally to reduce attrition in clinical trials and enhance their molecules’ formulation performance through its nanoforming services. The Company’s patented and scalable Controlled Expansion of Supercritical Solutions (CESS®) technology produces nanoformed API particles as small as 10nm. This enables poorly soluble molecules in the pharmaceutical pipeline to progress into clinical development by increasing their rate of dissolution and by improving their bioavailability. Nanoform’s unique technology provides novel opportunities in many value-enhancing drug delivery applications.
www.nanoform.com